Skip to main
BBOT

BBOT Stock Forecast & Price Target

BBOT Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BridgeBio Oncology is well positioned for success due to their focus on addressing KRAS and PI3Kα oncogenes in cancer, with promising inhibitors and potential best-in-class treatments. Their strong financial position and addition of an experienced executive also bode well for the company's potential for success in the oncology market.

Bears say

BridgeBio Oncology is facing numerous risks and challenges that could significantly impact their future and target price. Some of these include safety concerns, regulatory hurdles, and intense competition in the KRAS G12C inhibitor class that has already set a low efficacy and safety bar with little clinically meaningful benefit. Additionally, the company's novel approach to selectively targeting PI3Kα while sparing glucose homeostasis may not translate to significant clinical benefits, and their monotherapy and combination trials in different cancer types are still early and require further validation.

BBOT has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BridgeBio Oncology Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BridgeBio Oncology Therapeutics Inc (BBOT) Forecast

Analysts have given BBOT a Buy based on their latest research and market trends.

According to 9 analysts, BBOT has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BridgeBio Oncology Therapeutics Inc (BBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.